
Aspirin vs. Enoxaparin for Preventing Symptomatic Venous Thromboembolism in Hip or Knee Arthroplasty

Aspirin vs. Enoxaparin for Preventing Symptomatic Venous Thromboembolism in Hip or Knee Arthroplasty
Effect of Aspirin vs Enoxaparin on Symptomatic Venous Thromboembolism in Patients Undergoing Hip or Knee Arthroplasty: The CRISTAL Randomized Trial
JAMA. 2022 Aug 23;328(8):719-727.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
9711 patients with osteoarthritis undergoing a hip or knee arthroplasty procedure at one of 31 participating hospitals were randomized (in this hospital-level, cluster-randomized, crossover, non-inferiority trial) to receive aspirin (n=5675) or enoxaparin (n=4036) for the prevention of symptomatic venous thromboembolism (VTE). The primary outcome of interest was symptomatic VTE within 90 days, inc...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!

Join the Conversation
Please Login or Join to leave comments.